ClinicalTrials.gg

Program

empasiprubart

Also written as “Empasiprubart IV”, “ARGX-117” and “Empasiprubart”.

Its studies are mostly in Polyradiculoneuropathy, Chronic Inflammatory Demyelinating · Dermatomyositis · Myasthenia Gravis · Guillain-Barre Syndrome · Delayed Graft Function, led by argenx.

Furthest: phase 3, since Dec 16, 202413 company-led studies, 10 open or runningNext primary completion: Nov 2026 (phase 2)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
argenx1310 open or runningphase 3since Dec 16, 2024Aug 26, 2020Nov 2026phase 2 · NCT06284954

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Aug 26, 2020First study: phase 1 study in Healthy VolunteersFirst studyNCT04532125 · 110 enrolled · Netherlands
  2. Nov 5, 2021Phase 2 study in Multifocal Motor NeuropathyNCT05225675 · 54 enrolled · United States, Austria, Belgium and more
  3. May 17, 2022Phase 2 study in Multifocal Motor Neuropathy (MMN)NCT05405361 · 51 enrolled · United States, Austria, Belgium and more
  4. Jun 8, 2023Phase 2 study in Delayed Graft FunctionNCT05907096 · 103 enrolled · United States, Australia, Austria and more
  5. Feb 22, 2024Phase 2 study in DermatomyositisNCT06284954 · 3 enrolled · United States, Georgia, Greece and more
  6. Dec 16, 2024Phase 3 study in Multifocal Motor Neuropathy (MMN)NCT06742190 · 154 enrolled · United States, Australia, Austria and more
  7. Mar 26, 2025Phase 3 study in Polyradiculoneuropathy, Chronic Inflammatory DemyelinatingNCT06920004 · 218 planned · United States, Argentina, Australia and more
  8. Jul 22, 2025Phase 3 study in Polyradiculoneuropathy, Chronic Inflammatory DemyelinatingNCT07091630 · 160 planned · United States, Argentina, Austria and more
  9. May 20, 20262 phase 1 studiesNCT07610564, NCT07612020
  10. Jun 5, 2026Phase 3 study in Polyradiculoneuropathy, Chronic Inflammatory DemyelinatingNCT07638566
  11. Jun 23, 2026Phase 2 study in Myasthenia GravisNCT07673627 · 40 planned · United States, Belgium, Greece and more
  12. Sep 10, 2026Phase 2 study in Guillain-Barre SyndromeNCT07821762 · 63 planned
  13. Nov 13, 2026Phase 3 study withdrawnStudy stoppedNCT07638566 · “An alternative study design is under consideration.”

Ahead

  1. Nov 2026Primary completion: phase 2 study in DermatomyositisNCT06284954
  2. Mar 2027Primary completion: phase 1 study in Healthy VolunteersNCT07612020
  3. Sep 2027Primary completion: phase 3 study in Polyradiculoneuropathy, Chronic Inflammatory DemyelinatingNCT06920004
  4. Oct 2027Primary completion: phase 2 study in Myasthenia GravisNCT07673627

TargetBeta

Not stated by its company or a source we have read. Most early programs say nothing of it.

Studies

All 13 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT07821762Guillain-Barre Syndrome2Not yet recruitingJan 202863
NCT07673627Myasthenia Gravis · United States, Belgium, Greece and more2RecruitingOct 202740
NCT07638566Polyradiculoneuropathy, Chronic Inflammatory Demyelinating3WithdrawnApr 20280
NCT07612020Healthy Volunteers · Canada1RecruitingMar 2027130
NCT07610564Multifocal Motor Neuropathy (MMN) · United States, Georgia1RecruitingFeb 1, 202860
NCT07091630Polyradiculoneuropathy, Chronic Inflammatory Demyelinating · United States, Argentina, Austria and more3RecruitingOct 7, 2027160
NCT06920004Polyradiculoneuropathy, Chronic Inflammatory Demyelinating · United States, Argentina, Australia and more3RecruitingSep 2027218
NCT06742190Multifocal Motor Neuropathy (MMN) · United States, Australia, Austria and more3Active, not recruitingSep 2026154
NCT06284954Dermatomyositis · United States, Georgia, Greece and more2Active, not recruitingNov 20263
NCT05907096Delayed Graft Function · United States, Australia, Austria and more2Active, not recruitingOct 16, 2025103
NCT05405361Multifocal Motor Neuropathy (MMN) · United States, Austria, Belgium and more2Active, not recruitingSep 30, 202951
NCT05225675Multifocal Motor Neuropathy · United States, Austria, Belgium and more2CompletedJun 4, 202454
NCT04532125Healthy Volunteers · Netherlands1CompletedAug 26, 2022110

How it is read

Names in the registry

  • “Empasiprubart IV”, 6 entries
  • “ARGX-117”, 4 entries
  • “empasiprubart”, 1 entry
  • “Empasiprubart”, 1 entry
  • “empasiprubart IV”, 1 entry

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.